EDIT - Editas Medicine - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

EDIT is currently covered by 15 analysts with an average price target of $3.27. This is a potential upside of $1.55 (90.12%) from yesterday's end of day stock price of $1.72.

Editas Medicine's activity chart (see below) currently has 112 price targets and 119 ratings on display. The stock rating distribution of EDIT is 54.76% BUY, 40.48% HOLD and 4.76% SELL.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 47.82% with an average time for these price targets to be met of 134.84 days.

Highest price target for EDIT is $12, Lowest price target is $1, average price target is $6.64.

Most recent stock forecast was given by JOEL BEATTY from BAIRD on 13-May-2025. First documented stock forecast 29-Feb-2016.

Currently out of the existing stock ratings of EDIT, 23 are a BUY (54.76%), 17 are a HOLD (40.48%), 2 are a SELL (4.76%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$4

$2.28 (132.56%)

19 days ago
(13-May-2025)

1/6 (16.67%)

$2.5 (166.67%)

26

Sell

$9

5 months 16 days ago
(16-Dec-2024)

2/2 (100%)

$0.14 (1.58%)

9

Buy

$5

$3.28 (190.70%)

$7

5 months 16 days ago
(16-Dec-2024)

2/5 (40%)

$3.52 (237.84%)

7

$3

$1.28 (74.42%)

$5

5 months 19 days ago
(13-Dec-2024)

8/12 (66.67%)

$1.56 (108.33%)

200

Hold

$3

$1.28 (74.42%)

$11

5 months 19 days ago
(13-Dec-2024)

4/8 (50%)

$1.56 (108.33%)

38

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is EDIT (Editas Medicine) average time for price targets to be met?

On average it took 134.84 days on average for the stock forecasts to be realized with a an average price target met ratio 47.82

Which analyst has the current highest performing score on EDIT (Editas Medicine) with a proven track record?

STEVEN SEEDHOUSE

Which analyst has the most public recommendations on EDIT (Editas Medicine)?

Steven Seedhouse works at RAYMOND JAMES and has 6 price targets and 4 ratings on EDIT

Which analyst is the currently most bullish on EDIT (Editas Medicine)?

Cory Kasimov with highest potential upside - $21.82

Which analyst is the currently most reserved on EDIT (Editas Medicine)?

Greg Harrison with lowest potential downside - -$0.72

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?